Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease - NEJM - 0 views
-
Nathan Goodyear on 05 Sep 17new study challenges the cholesterol = cardiovascular event story? Good science asks questions and challenges dogma. The authors claim the inflammatory hypothesis of atherothrombosis is yet unproven? Maybe they need to get out and read more. The point here Is not the drug in question, but the fact that a reduction in inflammation reduced recurrent cardiovascular events independent of cholesterol.